KR101402922B1 - Pharmaceutical composition and functional food for prevention or treatment of bone disease comprising the acer tegmentosum maxim extract - Google Patents
Pharmaceutical composition and functional food for prevention or treatment of bone disease comprising the acer tegmentosum maxim extract Download PDFInfo
- Publication number
- KR101402922B1 KR101402922B1 KR1020120082803A KR20120082803A KR101402922B1 KR 101402922 B1 KR101402922 B1 KR 101402922B1 KR 1020120082803 A KR1020120082803 A KR 1020120082803A KR 20120082803 A KR20120082803 A KR 20120082803A KR 101402922 B1 KR101402922 B1 KR 101402922B1
- Authority
- KR
- South Korea
- Prior art keywords
- extraction
- extract
- treatment
- bone
- pharmaceutical composition
- Prior art date
Links
- 239000000284 extract Substances 0.000 title claims abstract description 47
- 235000013376 functional food Nutrition 0.000 title claims abstract description 14
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 11
- 230000002265 prevention Effects 0.000 title claims abstract description 8
- 208000020084 Bone disease Diseases 0.000 title abstract description 9
- 241000580937 Acer tegmentosum Species 0.000 title 1
- 208000001132 Osteoporosis Diseases 0.000 claims abstract description 21
- 230000036541 health Effects 0.000 claims abstract description 11
- 239000004480 active ingredient Substances 0.000 claims abstract description 7
- 239000000203 mixture Substances 0.000 claims description 17
- 238000000605 extraction Methods 0.000 claims description 16
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 13
- 230000002401 inhibitory effect Effects 0.000 claims description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 4
- 238000000034 method Methods 0.000 claims description 4
- 230000011164 ossification Effects 0.000 claims description 4
- 206010065687 Bone loss Diseases 0.000 claims description 3
- 238000001816 cooling Methods 0.000 claims description 3
- 239000012046 mixed solvent Substances 0.000 claims description 3
- 238000010992 reflux Methods 0.000 claims description 3
- 238000002137 ultrasound extraction Methods 0.000 claims description 3
- 238000003809 water extraction Methods 0.000 claims description 3
- 206010031243 Osteogenesis imperfecta Diseases 0.000 claims 1
- 210000002997 osteoclast Anatomy 0.000 description 42
- 230000000694 effects Effects 0.000 description 21
- 210000000988 bone and bone Anatomy 0.000 description 19
- 230000004069 differentiation Effects 0.000 description 19
- 208000035896 Twin-reversed arterial perfusion sequence Diseases 0.000 description 18
- 210000004979 bone marrow derived macrophage Anatomy 0.000 description 16
- 210000004027 cell Anatomy 0.000 description 15
- 238000004458 analytical method Methods 0.000 description 11
- 238000002360 preparation method Methods 0.000 description 10
- 102100034404 Nuclear factor of activated T-cells, cytoplasmic 1 Human genes 0.000 description 8
- 101710151542 Nuclear factor of activated T-cells, cytoplasmic 1 Proteins 0.000 description 8
- 102000007568 Proto-Oncogene Proteins c-fos Human genes 0.000 description 8
- 108010071563 Proto-Oncogene Proteins c-fos Proteins 0.000 description 8
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 8
- 201000010099 disease Diseases 0.000 description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 8
- 102000004169 proteins and genes Human genes 0.000 description 8
- 108090000623 proteins and genes Proteins 0.000 description 8
- 206010039073 rheumatoid arthritis Diseases 0.000 description 8
- 210000002798 bone marrow cell Anatomy 0.000 description 7
- 239000003814 drug Substances 0.000 description 7
- 210000000963 osteoblast Anatomy 0.000 description 7
- 239000002243 precursor Substances 0.000 description 7
- 238000003753 real-time PCR Methods 0.000 description 7
- 238000010186 staining Methods 0.000 description 7
- 239000002253 acid Substances 0.000 description 6
- 239000012153 distilled water Substances 0.000 description 6
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 5
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 5
- 230000006378 damage Effects 0.000 description 5
- 230000003247 decreasing effect Effects 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 230000002188 osteogenic effect Effects 0.000 description 5
- 239000000546 pharmaceutical excipient Substances 0.000 description 5
- 238000001262 western blot Methods 0.000 description 5
- 102000003945 NF-kappa B Human genes 0.000 description 4
- 108010057466 NF-kappa B Proteins 0.000 description 4
- 238000013459 approach Methods 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 238000004113 cell culture Methods 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 4
- 235000019441 ethanol Nutrition 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 108020004999 messenger RNA Proteins 0.000 description 4
- 210000004663 osteoprogenitor cell Anatomy 0.000 description 4
- 239000002953 phosphate buffered saline Substances 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 208000006386 Bone Resorption Diseases 0.000 description 3
- 102000043136 MAP kinase family Human genes 0.000 description 3
- 108091054455 MAP kinase family Proteins 0.000 description 3
- 108010046938 Macrophage Colony-Stimulating Factor Proteins 0.000 description 3
- 102100028123 Macrophage colony-stimulating factor 1 Human genes 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- 229920001213 Polysorbate 20 Polymers 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 244000299461 Theobroma cacao Species 0.000 description 3
- 102000040945 Transcription factor Human genes 0.000 description 3
- 108091023040 Transcription factor Proteins 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 230000002378 acidificating effect Effects 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 230000024279 bone resorption Effects 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- 229940011871 estrogen Drugs 0.000 description 3
- 239000000262 estrogen Substances 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 239000000796 flavoring agent Substances 0.000 description 3
- 235000013373 food additive Nutrition 0.000 description 3
- 239000002778 food additive Substances 0.000 description 3
- -1 for example Substances 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 229910052500 inorganic mineral Inorganic materials 0.000 description 3
- 210000001503 joint Anatomy 0.000 description 3
- 230000007774 longterm Effects 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 239000011707 mineral Substances 0.000 description 3
- 235000010755 mineral Nutrition 0.000 description 3
- 230000026731 phosphorylation Effects 0.000 description 3
- 238000006366 phosphorylation reaction Methods 0.000 description 3
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 3
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 3
- 239000003755 preservative agent Substances 0.000 description 3
- 230000019491 signal transduction Effects 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- PFTAWBLQPZVEMU-DZGCQCFKSA-N (+)-catechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-DZGCQCFKSA-N 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- 206010005949 Bone cancer Diseases 0.000 description 2
- 208000018084 Bone neoplasm Diseases 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- 206010017076 Fracture Diseases 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 244000020551 Helianthus annuus Species 0.000 description 2
- 235000003222 Helianthus annuus Nutrition 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 240000007472 Leucaena leucocephala Species 0.000 description 2
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 2
- 206010027476 Metastases Diseases 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 2
- 238000011529 RT qPCR Methods 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- 230000003187 abdominal effect Effects 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 235000010443 alginic acid Nutrition 0.000 description 2
- 229920000615 alginic acid Polymers 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 239000003435 antirheumatic agent Substances 0.000 description 2
- 230000006907 apoptotic process Effects 0.000 description 2
- 239000003125 aqueous solvent Substances 0.000 description 2
- 206010003246 arthritis Diseases 0.000 description 2
- 235000013361 beverage Nutrition 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 230000037182 bone density Effects 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- ADRVNXBAWSRFAJ-UHFFFAOYSA-N catechin Natural products OC1Cc2cc(O)cc(O)c2OC1c3ccc(O)c(O)c3 ADRVNXBAWSRFAJ-UHFFFAOYSA-N 0.000 description 2
- 235000005487 catechin Nutrition 0.000 description 2
- 238000010609 cell counting kit-8 assay Methods 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 235000010980 cellulose Nutrition 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 235000019219 chocolate Nutrition 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 229950001002 cianidanol Drugs 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 235000009508 confectionery Nutrition 0.000 description 2
- 231100000135 cytotoxicity Toxicity 0.000 description 2
- 230000003013 cytotoxicity Effects 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 235000015203 fruit juice Nutrition 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 230000009401 metastasis Effects 0.000 description 2
- 238000010603 microCT Methods 0.000 description 2
- YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 2
- 230000003449 preventive effect Effects 0.000 description 2
- 238000004393 prognosis Methods 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 235000012222 talc Nutrition 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 239000002562 thickening agent Substances 0.000 description 2
- 210000000689 upper leg Anatomy 0.000 description 2
- 239000011534 wash buffer Substances 0.000 description 2
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 2
- WBYWAXJHAXSJNI-VOTSOKGWSA-M .beta-Phenylacrylic acid Natural products [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 description 1
- XZKIHKMTEMTJQX-UHFFFAOYSA-N 4-Nitrophenyl Phosphate Chemical compound OP(O)(=O)OC1=CC=C([N+]([O-])=O)C=C1 XZKIHKMTEMTJQX-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- 241000208140 Acer Species 0.000 description 1
- 206010001605 Alcohol poisoning Diseases 0.000 description 1
- 208000008822 Ankylosis Diseases 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 241000516950 Atheroides Species 0.000 description 1
- 238000009020 BCA Protein Assay Kit Methods 0.000 description 1
- 229940122361 Bisphosphonate Drugs 0.000 description 1
- 208000010392 Bone Fractures Diseases 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 101100421200 Caenorhabditis elegans sep-1 gene Proteins 0.000 description 1
- 102000055006 Calcitonin Human genes 0.000 description 1
- 108060001064 Calcitonin Proteins 0.000 description 1
- WBYWAXJHAXSJNI-SREVYHEPSA-N Cinnamic acid Chemical compound OC(=O)\C=C/C1=CC=CC=C1 WBYWAXJHAXSJNI-SREVYHEPSA-N 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 102000015775 Core Binding Factor Alpha 1 Subunit Human genes 0.000 description 1
- 108010024682 Core Binding Factor Alpha 1 Subunit Proteins 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- 240000000731 Fagus sylvatica Species 0.000 description 1
- 235000010099 Fagus sylvatica Nutrition 0.000 description 1
- KRHYYFGTRYWZRS-UHFFFAOYSA-M Fluoride anion Chemical compound [F-] KRHYYFGTRYWZRS-UHFFFAOYSA-M 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 208000037147 Hypercalcaemia Diseases 0.000 description 1
- 102000018251 Hypoxanthine Phosphoribosyltransferase Human genes 0.000 description 1
- 108010091358 Hypoxanthine Phosphoribosyltransferase Proteins 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- SFBODOKJTYAUCM-UHFFFAOYSA-N Ipriflavone Chemical compound C=1C(OC(C)C)=CC=C(C2=O)C=1OC=C2C1=CC=CC=C1 SFBODOKJTYAUCM-UHFFFAOYSA-N 0.000 description 1
- 206010023198 Joint ankylosis Diseases 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 206010027304 Menopausal symptoms Diseases 0.000 description 1
- 206010027452 Metastases to bone Diseases 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 208000003076 Osteolysis Diseases 0.000 description 1
- 239000002033 PVDF binder Substances 0.000 description 1
- 244000131316 Panax pseudoginseng Species 0.000 description 1
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 1
- 235000003140 Panax quinquefolius Nutrition 0.000 description 1
- 102000003982 Parathyroid hormone Human genes 0.000 description 1
- 108090000445 Parathyroid hormone Proteins 0.000 description 1
- 229920002230 Pectic acid Polymers 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 238000010802 RNA extraction kit Methods 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 235000005764 Theobroma cacao ssp. cacao Nutrition 0.000 description 1
- 235000005767 Theobroma cacao ssp. sphaerocarpum Nutrition 0.000 description 1
- 102100028787 Tumor necrosis factor receptor superfamily member 11A Human genes 0.000 description 1
- 101710178436 Tumor necrosis factor receptor superfamily member 11A Proteins 0.000 description 1
- 241000707822 Ulmus glabra Species 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 238000003916 acid precipitation Methods 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 230000001548 androgenic effect Effects 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 239000011260 aqueous acid Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 238000010009 beating Methods 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 150000004663 bisphosphonates Chemical class 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 230000018678 bone mineralization Effects 0.000 description 1
- 230000010478 bone regeneration Effects 0.000 description 1
- 235000008429 bread Nutrition 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 235000001046 cacaotero Nutrition 0.000 description 1
- BBBFJLBPOGFECG-VJVYQDLKSA-N calcitonin Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 BBBFJLBPOGFECG-VJVYQDLKSA-N 0.000 description 1
- 229960004015 calcitonin Drugs 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000000378 calcium silicate Substances 0.000 description 1
- 229910052918 calcium silicate Inorganic materials 0.000 description 1
- 235000012241 calcium silicate Nutrition 0.000 description 1
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 235000014171 carbonated beverage Nutrition 0.000 description 1
- 210000000845 cartilage Anatomy 0.000 description 1
- 210000003321 cartilage cell Anatomy 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 230000005754 cellular signaling Effects 0.000 description 1
- 235000013351 cheese Nutrition 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 235000013985 cinnamic acid Nutrition 0.000 description 1
- 229930016911 cinnamic acid Natural products 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 238000002247 constant time method Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 231100000263 cytotoxicity test Toxicity 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- XEYBRNLFEZDVAW-ARSRFYASSA-N dinoprostone Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XEYBRNLFEZDVAW-ARSRFYASSA-N 0.000 description 1
- 229960002986 dinoprostone Drugs 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- PXEDJBXQKAGXNJ-QTNFYWBSSA-L disodium L-glutamate Chemical compound [Na+].[Na+].[O-]C(=O)[C@@H](N)CCC([O-])=O PXEDJBXQKAGXNJ-QTNFYWBSSA-L 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 229920001971 elastomer Polymers 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 201000006828 endometrial hyperplasia Diseases 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000002532 enzyme inhibitor Substances 0.000 description 1
- 229940125532 enzyme inhibitor Drugs 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 239000011536 extraction buffer Substances 0.000 description 1
- 235000013861 fat-free Nutrition 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 229940091249 fluoride supplement Drugs 0.000 description 1
- 238000011010 flushing procedure Methods 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 235000008434 ginseng Nutrition 0.000 description 1
- 229960002449 glycine Drugs 0.000 description 1
- 230000003394 haemopoietic effect Effects 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 230000000148 hypercalcaemia Effects 0.000 description 1
- 208000030915 hypercalcemia disease Diseases 0.000 description 1
- 235000015243 ice cream Nutrition 0.000 description 1
- 238000007654 immersion Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 229960005431 ipriflavone Drugs 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- VMPHSYLJUKZBJJ-UHFFFAOYSA-N lauric acid triglyceride Natural products CCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCC)COC(=O)CCCCCCCCCCC VMPHSYLJUKZBJJ-UHFFFAOYSA-N 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 229940069445 licorice extract Drugs 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 208000029791 lytic metastatic bone lesion Diseases 0.000 description 1
- 239000000845 maltitol Substances 0.000 description 1
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 1
- 235000010449 maltitol Nutrition 0.000 description 1
- 229940035436 maltitol Drugs 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- WBYWAXJHAXSJNI-UHFFFAOYSA-N methyl p-hydroxycinnamate Natural products OC(=O)C=CC1=CC=CC=C1 WBYWAXJHAXSJNI-UHFFFAOYSA-N 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 235000013923 monosodium glutamate Nutrition 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 230000030991 negative regulation of bone resorption Effects 0.000 description 1
- 201000008383 nephritis Diseases 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 231100001083 no cytotoxicity Toxicity 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 1
- 231100000956 nontoxicity Toxicity 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 230000004072 osteoblast differentiation Effects 0.000 description 1
- 230000001599 osteoclastic effect Effects 0.000 description 1
- 230000000010 osteolytic effect Effects 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- 239000000199 parathyroid hormone Substances 0.000 description 1
- 229960001319 parathyroid hormone Drugs 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- LCLHHZYHLXDRQG-ZNKJPWOQSA-N pectic acid Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)O[C@H](C(O)=O)[C@@H]1OC1[C@H](O)[C@@H](O)[C@@H](OC2[C@@H]([C@@H](O)[C@@H](O)[C@H](O2)C(O)=O)O)[C@@H](C(O)=O)O1 LCLHHZYHLXDRQG-ZNKJPWOQSA-N 0.000 description 1
- 210000003049 pelvic bone Anatomy 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 238000000554 physical therapy Methods 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 235000013550 pizza Nutrition 0.000 description 1
- 231100000572 poisoning Toxicity 0.000 description 1
- 230000000607 poisoning effect Effects 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000010318 polygalacturonic acid Substances 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000001508 potassium citrate Substances 0.000 description 1
- 229960002635 potassium citrate Drugs 0.000 description 1
- QEEAPRPFLLJWCF-UHFFFAOYSA-K potassium citrate (anhydrous) Chemical compound [K+].[K+].[K+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O QEEAPRPFLLJWCF-UHFFFAOYSA-K 0.000 description 1
- 235000011082 potassium citrates Nutrition 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000002028 premature Effects 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 208000037821 progressive disease Diseases 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- XEYBRNLFEZDVAW-UHFFFAOYSA-N prostaglandin E2 Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CC=CCCCC(O)=O XEYBRNLFEZDVAW-UHFFFAOYSA-N 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000000751 protein extraction Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 239000012723 sample buffer Substances 0.000 description 1
- 235000013580 sausages Nutrition 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 230000001953 sensory effect Effects 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 210000003625 skull Anatomy 0.000 description 1
- 230000000391 smoking effect Effects 0.000 description 1
- 235000011888 snacks Nutrition 0.000 description 1
- 229940073490 sodium glutamate Drugs 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 235000014347 soups Nutrition 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 210000005222 synovial tissue Anatomy 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 235000013616 tea Nutrition 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- QYSXJUFSXHHAJI-YRZJJWOYSA-N vitamin D3 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C\C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-YRZJJWOYSA-N 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 230000003313 weakening effect Effects 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/20—Aceraceae (Maple family)
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/306—Foods, ingredients or supplements having a functional effect on health having an effect on bone mass, e.g. osteoporosis prevention
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation, decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Physical Education & Sports Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Rheumatology (AREA)
- Medicinal Chemistry (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Mycology (AREA)
- Pharmacology & Pharmacy (AREA)
- Botany (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Medical Informatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
본 발명은 골질환의 예방 또는 치료에 효과적인 천연 추출물로서, 산천목 추출물을 유효성분으로 함유하는 골질환의 예방 또는 치료용 약학적 조성물 및 건강기능식품에 관한 것이다. The present invention relates to a natural extract effective for prevention or treatment of bone diseases, a pharmaceutical composition for preventing or treating osteoporosis, which contains an extract of Sanseonchon as an active ingredient, and a health functional food.
Description
본 발명은 산천목 추출물을 유효성분으로 함유하는 골질환의 예방 또는 치료용 약학적 조성물 및 건강기능식품에 관한 것이다.
TECHNICAL FIELD The present invention relates to a pharmaceutical composition and a health functional food for preventing or treating osteoporosis, which contains an extract of Sanskrit, as an active ingredient.
정상적인 뼈의 재형성과정은 뼈 형성과 뼈 흡수의 균형으로 이루어지며, 이러한 뼈 형성과 뼈 흡수는 크게 세 가지 세포, 연골세포, 조골세포(osteoblast) 및 파골세포(osteoclast)의 상호작용에 의해 이루어진다. 특히, 조골세포의 증식과 분화는 뼈의 석회화와 밀접한 관계가 있으며 조골세포에서 중요한 전사인자인 RUNX2에 변이가 생기거나 발현량이 감소하면 뼈의 석회화가 일어나지 않는다. RANKL(receptor activator of NF-kB ligand)은 조골세포의 분화과정 동안에 발현되어 파골세포 분화를 조절하는 것으로 알려져 있고 OPG(Osteoprotegrin) 역시 조골세포에서 발현되어 RANKL의 역할을 억제함으로써 파골세포의 분화를 억제하는 인자로 알려져 있다. 또한, RANKL은 파골세포 분화의 핵심 유발인자로, 세포 표면의 수용체 RANK와 결합하여 파골세포 분화에 관여하는 다양한 분자의 발현을 조절하여 파골세포 분화를 촉진시키는 것으로 알려져 있다[Takayanagi H., Osteoimmunology: shared mechanisms and crosstalk between the immune and bone systems., Nat Rew immunol. 2007 Apr; 7(4): p292-304].
Normal bone reshaping is a balance of bone formation and bone uptake, and this bone formation and bone uptake is largely due to the interaction of three cells, cartilage cells, osteoblasts and osteoclasts . In particular, the proliferation and differentiation of osteoblasts are closely related to bone calcification, and bone metastases do not occur when mutations or decreased expression levels of RUNX2, an important transcription factor in osteoblast cells, occur. It is known that RANKL (receptor activator of NF-kB ligand) is expressed during osteoblast differentiation and regulates osteoclast differentiation. OPG (osteoprotegrin) is also expressed in osteoblasts to inhibit osteoclast differentiation by inhibiting the role of RANKL Is known as an argument. In addition, RANKL is a key inducer of osteoclast differentiation and is known to bind osteoclast differentiation involved in osteoclast differentiation by binding to RANK receptor on the cell surface [Takayanagi H., Osteoimmunology: shared mechanisms and crosstalk between the immune and bone systems., Nat Rew immunol. 2007 Apr; 7 (4): p292-304).
한편, 파골세포 분화, 형성 및 활성 증가는 골다공증 유발, 고형암 및 조혈악성종양과 같은 몇몇 암에 고칼슘혈증 또는 골전이를 유발 및 류마티즘 관절염에 골손실을 증가시키는 것으로 알려져 있다[Rodan GA, Martin TJ., Therapeutic approaches to bone diseases, Science. 2000 Sep 1: 289(5484): p1508-1514, Roodman GD, Mechanisms of Bone Metastasis, N Engl J Med. 2004 Apr 15; 350(16); p1655-1664].
On the other hand, it is known that osteoclast differentiation, formation and activity increase cause hypercalcemia or bone metastasis in some cancers such as osteoporosis induced, solid tumors and hematopoietic malignant tumors and increase bone loss in rheumatoid arthritis [Rodan GA, Martin TJ. , Therapeutic approaches to bone diseases, Science. 2000 Sep 1: 289 (5484): p1508-1514, Roodman GD, Mechanisms of Bone Metastasis, N Engl J Med. 2004 Apr 15; 350 (16); p1655-1664].
골다공증(osteoporosis)은 여러 가지 원인에 의하여 뼈의 질량이 감소하고 뼈 조직의 미세구조의 퇴화로 골절 위험이 지속적으로 증가하는 질환으로 뼈를 구성하는 미네랄(특히 칼슘)과 기질이 감소한 상태이며, 골재형성의 균형이 깨져서 파골작용이 조골작용보다 증가된 상태에서 발생한다. 정상적인 뼈 내부는 그물망처럼 치밀한 구조를 이루고 있으나, 골다공증의 경우에는 골미세구조 사이의 간격에 넓어지고 미세구조가 얇아져 약해짐으로써 조그만 충격에도 뼈가 쉽게 골절될 위험이 증가하는 질환으로 폐경기 이후 골다공증, 70세 이상의 남녀 노인에게 서서히 발생하며 골반골과 척추뼈의 점진적인 골 손실을 가져오는 노년기 골다공증 및 연령에 상관없이 질병이나 약물, 알코올, 흡연, 사고로 인해 발생하는 2차 골다공증으로 분류된다.
Osteoporosis is a disease in which the bone mass is decreased by various causes and the risk of fracture is continuously increased due to the degeneration of the microstructure of the bone tissue. The bone mineral structure (especially calcium) and the matrix are decreased, The formation of balance is broken and osteoclastic activity occurs in the state of increased osteotomy. Inside the normal bone is a dense structure like a net, but in the case of osteoporosis, the widening of the gap between the bone microstructure and the thinning of the microstructure leads to the weakening of the bone, It is categorized as osteoporosis in the elderly, which gradually develops in men and women aged 70 years or older, with progressive bone loss in the pelvic bone and vertebrae, and secondary osteoporosis due to disease, drug, alcohol, smoking and accident regardless of age.
골다공증은 현재 가장 중요한 사회적 문제 중 하나로, 미국의 경우 매년 약 26 만명의 여성들에게 유발되고 있으며, 이중 약 12 내지 20% 정도는 사망에 이르고 있다. 사회가 노령화되고 여성들의 사회참여가 활발해지고 있는 상황에서 노인들이나 폐경 후 여성들의 골다공증 및 골다공증으로 인한 골절은 심각한 문제를 야기한다.
Osteoporosis is one of the most important social problems nowadays. In the United States, about 262,000 women are born every year, of which about 12 to 20% die. As society becomes aging and women become more active in society, fractures caused by osteoporosis and osteoporosis of elderly or postmenopausal women cause serious problems.
현재 골다공증 치료제로 사용되고 있는 물질로는 에스트로겐(estrogen), 남성화 스테로이드 호르몬(androgenic anagolic ateroid), 칼슘 제제, 인삼염, 불소 제제, 이프리플라본(Ipriflavone), 비타민 D3 등이 있다. 에스트로겐은 조골세포의 세포고사를 억제하여 세포의 생존기간을 증가시키고 파골세포의 세포고사를 촉진하여 세포의 생존기간을 감소시켜 폐경증상의 치료와 골밀도 유지에 어느 정도 효과적인 방법이나 유방암, 자궁내막 증식증 등을 유발하는 부작용이 있다. 이외에도 파골세포의 활성을 억제하여 골파괴를 억제시키거나 조골세포의 증식을 통해 골재생 단위의 활성을 증가시키는 약물로 칼시토닌, 부갑상선호르몬, 비스포스포네이트 제제 등이 있다. 그러나, 기존 골다공증 치료약제들은 골흡수만을 차단시키거나 골형성을 촉진시키는 효능만을 갖으며 장기간 투여시 많은 부작용을 유발하고 있다. 따라서 장기간 투여에도 지속적인 골밀도 증가 효과를 나타내고 부작용이 적은 안전한 예방 및 치료제 개발이 요구되고 있다.
Currently, estrogen, androgenic anagolic atheroid, calcium, ginseng, fluoride, Ipriflavone, and vitamin D 3 are used in osteoporosis treatment. Estrogen suppresses cell apoptosis of osteoblast cells, thereby increasing the cell survival period. It promotes osteoclast cell apoptosis, thereby decreasing the cell survival period. Thus, estrogen is effective for treatment of menopausal symptoms and for maintaining bone density. Breast cancer, endometrial hyperplasia And the like. In addition, there are calcitonin, parathyroid hormone, and bisphosphonate preparations as a drug that inhibits osteoclast activity and inhibits bone destruction or increases the activity of bone regeneration unit through osteoblast proliferation. However, existing osteoporosis medicines have only the effect of blocking bone resorption or promoting bone formation and causing many side effects in long-term administration. Therefore, it is required to develop a safe preventive and therapeutic agent that exhibits a continuous increase in bone mineral density even after long-term administration and has fewer side effects.
또한, 류마티스 관절염은 아직 원인이 밝혀지지 않은 주로 관절을 침범하는 만성, 전신성, 염증성 질환으로, 조조강직(관절염의 초기증상으로 손가락 등이 뻣뻣해지는 증상), 대칭적 관절 침범, 손 관절을 잘 침범하는 등의 특징이 있다. 관절염은 일반적으로 말초 관절부터 시작해 점점 근위 관절로 진행하며, 염증이 잘 조절이 되지 않은 경우에는 계속 자라나는 활성화된 활막조직에 의해 주위의 연골과 뼈가 파괴되어 관절의 변형이 초래된다. 류마티스 관절염의 치료는 최근 20년 동안 질병의 병인과 예후에 대한 이해와 새로운 비생물학적, 생물학적 항류마티스 약제의 개발 등을 통해 많이 변화하였다. 과거에는 휴식, 물리치료, 아스피린, 비스테로이드성 항염증제 등으로 일차적으로 치료하고, 치료에 반응 않거나 관절 손상 발생시, 부작용이 적은 항류마티스 약제부터 시작하여 강한 면역억제제로 올라가는 피라미드식 접근에 의한 단계적 치료가 류마티스 관절염 치료의 근간을 이루었다. 이 피라미드식 접근 방법은 류마티스 관절염이 예후가 좋고 보존적 치료에 반응을 잘하는 양성 질병의 개념에서 출발한 치료 전략이다.
In addition, rheumatoid arthritis is a chronic, systemic, and inflammatory disease that mainly affects joints that have not yet been diagnosed. The symptoms of premature ankylosis (stiffness of the fingers as an early symptom of arthritis), symmetrical joint involvement, And so on. Arthritis usually progresses from the peripheral joint to the proximal joint, and if the inflammation is not well regulated, the active synovial tissue that continues to grow destroys the surrounding cartilage and bone, resulting in deformation of the joint. Treatment of rheumatoid arthritis has changed significantly over the past two decades through understanding of the etiology and prognosis of the disease and the development of new abiotic and biological antirheumatic agents. In the past, treatment with rest, physical therapy, aspirin, non-steroidal antiinflammatory drugs, and treatment with anti-rheumatic drugs that do not respond to treatment or joint damage, It is the basis of rheumatoid arthritis treatment. This pyramidal approach is a therapeutic strategy that starts with the concept of benign disease in which rheumatoid arthritis is good for prognosis and well responsive to conservative treatment.
그러나, 1989년 Wilske와 Healey가 피라미드식 접근의 한계를 지적하고 이러한 방법이 관절의 손상을 효과적으로 억제하지 못하는 것으로 보고한 이후, 많은 역학 및 임상 연구 결과들을 통해 치료 패러다임이 바뀌게 되었다. 류마티스 과절염은 양성 질환이 아니고, 만성 진행성 질환이며, 피라미드식 접근 방식이 질병의 기능적, 임상적, 방사선학적 손상을 막을 수 없고, 이차 약제의 독작용이 생각만큼 심하지 않다는 것을 알게 되었다. 또한, 류마티스 관절염 환자의 사망률이 증가하여 평균 수명이 짧음을 알게 되었으며, 방사선 학적 골파괴가 환자의 70% 이상에서 급격히 진행됨이 확인되었다. 따라서 장기간 투여에도 지속적인 치료 효과를 나타내고 부작용이 적은 안전한 예방 및 치료제 개발이 요구되고 있다.
However, after 1989 Wilske and Healey pointed out the limitations of the pyramidal approach and reported that this method did not effectively suppress joint damage, many epidemiological and clinical studies have changed the therapeutic paradigm. Rheumatism and flushing are not benign, chronic progressive diseases, and we have found that pyramidal approaches can not prevent functional, clinical, and radiological damage to the disease, and toxic effects of secondary drugs are not as severe as they might seem. In addition, we found that the mortality rate of patients with rheumatoid arthritis increased and the mean life span was short. Radiological bone destruction was found to progress rapidly in more than 70% of patients. Therefore, it is required to develop a safe preventive and therapeutic agent which shows a continuous therapeutic effect even with long-term administration and has few side effects.
이에, 본 발명자들은 골다공증 또는 류마티스 관절염과 같은 골질환을 예방 또는 치료하기 위한 천연 약재를 연구하던 중, 산천목 추출물이 TRAP 활성, 다핵성 파골세포 형성 억제 및 골흡수능 억제등을 보임으로써 골질환의 예방 또는 치료에 효능이 있음을 확인하고 본 발명을 완성하였다.
Accordingly, the present inventors have been studying natural medicines for the prevention or treatment of osteoporosis such as osteoporosis or rheumatoid arthritis. The present inventors have found that the extract of Sanseongcheon tree shows TRAP activity, inhibition of formation of polynuclear osteoclasts and inhibition of bone resorption, Prevention or treatment, and completed the present invention.
본 발명의 목적은 골질환을 예방 또는 치료할 수 있는 산천목 추출물을 유효성분으로 함유하는 약학적 조성물 또는 건강기능식품을 제공하기 위한 것이다.
It is an object of the present invention to provide a pharmaceutical composition or a health functional food containing an extract of Sanseonggang, which can prevent or treat bone diseases, as an active ingredient.
상기의 과제를 해결하기 위하여, 본 발명은 산천목 추출물을 유효성분으로 함유하는 골질환의 예방 또는 치료용 약학적 조성물을 제공한다.
In order to solve the above-mentioned problems, the present invention provides a pharmaceutical composition for preventing or treating osteoporosis, which contains an extract of Sanskrit, as an active ingredient.
본 발명에서 사용되는 용어 '산천목'은, 단풍나무과에 속하는 식물로서 산청목, 벌나무 및 산겨릅나무라고 불리우며, 잎은 넓고 어린 줄기는 연한 녹색이며 줄기가 매우 연하여 잘 부러지며 껍질이 두껍고 재질은 희고 가볍다. 산천목은 독성이 없으므로 어떤 체질에도 부작용이 거의 없는 약재이며, 맛이 담백하여 청혈제와 이수제로도 쓰인다. 간의 온도를 정상으로 회복시키고 수분이 잘 배설되게 하여 한국의 민간에서는 그 잎과 목부를 간염, 간경화, 간암 등의 간질환 치료제 및 백혈병, 당뇨병, 신장염이나 부종을 치료하는데 사용하고 있으며, 알콜 해독의 목적으로도 사용하고 있다. 또한, 음주시 산천목 목부 추출물을 복용하면 주독을 예방할 수 있다고 보고되어 있다. 본 발명의 산천목 추출물은 산천목을 물, C1 -4 알코올 또는 이들의 혼합 용매로 추출하여 제조되는 것이 바람직하다.
As used herein, the term "mountain tree neck" is a plant belonging to the maple family, and is called schanpom, beech, and mountain elm. The leaf is wide, the young stem is pale green, the stem is very soft and broken, It is white and light. It is a medicinal herb that has no side effects on any constitution because it has no toxicity. It is used to treat liver diseases such as hepatitis, liver cirrhosis and liver cancer, leukemia, diabetes, nephritis and edema, and it is used in the treatment of alcohol poisoning. It is also used for the purpose. In addition, it is reported that taking the extract of Sangcheon Throat when drinking alcohol can prevent the poisoning. Mountains and rivers neck extract of the present invention is preferably prepared by extracting the mountains and rivers neck with water, C 1 -4 alcohol or a mixed solvent thereof.
상기 추출은 열수 추출, 초음파 추출, 상온추출, 냉침 추출, 환류 냉각 추출 또는 증기 추출인 것이 바람직하나, 이에 제한되는 것은 아니다.
The extraction is preferably a hot water extraction, an ultrasonic extraction, a room temperature extraction, a cold extraction, a reflux cooling extraction, or a steam extraction, but is not limited thereto.
본 발명에서 사용되는 용어 '골질환'은, 골밀도가 감소되어 일어나는 모든 질환을 의미하는 것으로, 골다공증, 골형성 부전증, 류마티스 관절염, 골암 또는 골전이암 등을 포함한다.
The term 'bone disease' as used in the present invention means all diseases caused by a decrease in bone density, and includes osteoporosis, osteoporosis, rheumatoid arthritis, bone cancer or bone cancer.
본 발명에서는 산천목 추출물을 함유하는 조성물이 골질환의 예방 또는 치료에 효과가 있음을 확인하였다. 본 발명의 일 실시예에 따르면, 골질환의 지표가 되는 파골세포 분화마커인 TRAP 활성, 다핵성파골세포 형성 억제 및 골흡수능 억제 효과를 확인함으로써, 골질환의 예방 또는 치료 효능이 있음을 확인하였다.
In the present invention, it has been confirmed that a composition containing an extract of Sanskrit tree is effective for preventing or treating bone diseases. According to one embodiment of the present invention, TRAP activity as an osteoclast differentiation marker which is an index of bone disease, inhibition of formation of polynuclear osteoclast, and inhibitory effect on bone resorption ability were confirmed, .
본 발명에서 사용되는 용어 '예방'은, 상기 산천목 추출물을 함유하는 조성물의 투여로 질환을 억제 또는 지연시키는 모든 행위를 의미한다. 또한, 본 발명에서 사용되는 용어 '치료'는, 상기 산천목 추출물을 함유하는 조성물의 투여로 질환의 증세가 호전되거나 완치되는 모든 행위를 의미한다.
As used herein, the term " prevention " means any action that inhibits or delays disease by the administration of a composition containing the extract from the mountain. The term " treatment " used in the present invention means all the actions of improving or alleviating the symptom of the disease by administration of the composition containing the extract of the mountain tree.
본 발명의 조성물은 투여를 위하여, 상기 기재한 유효성분 이외에 약학적으로 허용 가능한 담체, 부형제 또는 희석제를 포함할 수 있다. 상기 담체, 보형제 및 희석제로는 락토오스, 덱스트로오스, 수크로오스, 소르비톨, 만니톨, 자일리톨, 에리스리톨, 말티톨, 전분, 아카시아 고무, 알지네이트, 젤라틴, 칼슘 포스페이트, 칼슘 실리케이트, 셀룰로오스, 메틸 셀룰로오스, 미정질 셀룰로오스, 폴리비닐 피롤리돈, 물, 메틸히드록시벤조에이트, 프로필히드록시벤조에이트, 탈크, 마그네슘 스테아레이트 및 광물유를 들 수 있다.
The composition of the present invention may contain, for administration, a pharmaceutically acceptable carrier, excipient or diluent in addition to the above-described effective ingredients. The carrier, the beating agent and the diluent include lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, acacia rubber, alginate, gelatin, calcium phosphate, calcium silicate, cellulose, methylcellulose, microcrystalline cellulose , Polyvinylpyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate, and mineral oil.
본 발명의 조성물은 각각 통상의 방법에 따라 산제, 과립제, 정제, 캡슐제, 현탁액, 에멀젼, 시럽, 에어로졸 등의 경구형 제형, 외용제, 좌제 또는 멸균 주사 용액의 형태로 제형화하여 사용할 수 있다. 상세하게는, 제형화할 경우 통상 사용하는 충진제, 중량제, 결합제, 습윤제, 붕해제, 계면활성제 등의 희석제 또는 부형제를 사용하여 조제될 수 있다. 경구투여를 위한 고형제제로는 정제, 환제, 산제, 과립제, 캡슐제 등을 포함하나, 이에 한정되는 것은 아니다. 이러한 고형제제는 상기 산천목 추출물에 적어도 하나 이상의 부형제, 예를 들면, 전분, 칼슘 카보네이트, 수크로오스, 락토오스, 젤라틴 등을 섞어 조제될 수 있다. 또한, 단순한 부형제 이외에 마그네슘 스테아레이트, 탈크 같은 윤활제들도 사용될 수 있다. 경구를 위한 액상물, 리퀴드 파라핀 이외에 여러 가지 부형제, 예를 들면 습윤제, 감미제, 방향제, 보존제 등을 첨가하여 조제될 수 있다. 비경구 투여를 위한 제제는 멸균된 수용액, 비수성 용제, 현탁제, 유제, 동결건조 제제 및 과제를 포함한다. 비수성 용제 및 현탁제로는 프로필렌글리콜, 폴리에틸렌 글리콜, 올리브 오일과 같은 식물성 오일, 에틸올레이트와 같은 주사 가능한 에스테르 등이 사용될 수 있다. 좌제의 기제로는 위텝솔, 마크로솔, 트윈 61, 카카오지, 라우린지, 글리세로 젤라틴 등이 사용될 수 있다.
The composition of the present invention may be formulated in the form of oral, granule, tablet, capsule, suspension, emulsion, syrup, aerosol or the like oral preparation, external preparation, suppository or sterilized injection solution according to a conventional method. In detail, when formulating, it can be prepared by using diluents or excipients such as fillers, weighing agents, binders, humectants, disintegrants, surfactants and the like which are generally used. Solid formulations for oral administration include, but are not limited to, tablets, pills, powders, granules, capsules, and the like. Such a solid preparation can be prepared by mixing at least one excipient, for example, starch, calcium carbonate, sucrose, lactose, gelatin, In addition to simple excipients, lubricants such as magnesium stearate and talc may also be used. Liquid preparations for oral administration, liquid paraffin, and various excipients such as wetting agents, sweeteners, fragrances, preservatives and the like. Formulations for parenteral administration include sterile aqueous solutions, non-aqueous solvents, suspensions, emulsions, lyophilized preparations and tasks. Non-aqueous solvents and suspensions may include propylene glycol, polyethylene glycol, vegetable oils such as olive oil, injectable esters such as ethyl oleate, and the like. As a base for suppositories, it is possible to use witepsol, macrosole, tween 61, cacao paper, laurin, glycerogelatin and the like.
본 발명의 조성물은 목적하는 방법에 따라 경구 투여하거나 비경구투여(예를 들어, 정맥 내, 피하, 복강 내 또는 국소에 적용)할 수 있으며, 투여량은 환자의 상태 및 체중, 질병의 정도, 약물형태, 투여 경로 및 시간에 따라 다르지만, 당업자에 의해 적절하게 선택될 수 있다. 상기 산천목 추출물의 일일 투여량은 바람직하게는 1 mg/kg 내지 1500 mg/kg이며, 필요에 따라 일일 1회 내지 수회로 나누어 투여할 수 있다.
The composition of the present invention may be administered orally or parenterally (for example, intravenously, subcutaneously, intraperitoneally or topically) depending on the desired method, and the dose may be determined depending on the condition and weight of the patient, The mode of administration, the route of administration, and the time, but may be suitably selected by those skilled in the art. The daily dose of the acidophylline extract is preferably 1 mg / kg to 1500 mg / kg, and may be administered once or several times a day, if necessary.
또한, 본 발명은 산천목 추출물을 유효성분으로 함유하는 골질환의 예방 또는 개선용 건강기능식품 조성물을 제공한다.
The present invention also provides a health functional food composition for preventing or ameliorating osteoporosis, which contains an extract of Sanskrit, as an active ingredient.
상기 건강기능식품은 여러 가지 영양제, 비타민, 광물(전해질), 합성 풍미제 및 천연 풍미제 등의 풍미제, 착색제 및 중진제(치즈, 초콜릿 등), 펙트산 및 그의 염, 알긴산 및 그의 염, 유기산, 보호성 콜로이드 증점제, pH 조절제, 안정화제, 방부제, 글리세린, 알코올, 탄산 음료에 사용되는 탄산화제 등을 함유할 수 있다. 그 밖에 천연 과일 주스 및 과일 주스 및 야채 음료의 제조를 위한 과육을 함유할 수 있다. 이러한 성분은 독립적으로 또는 조합하여 사용할 수 있다. 또한, 건강기능식품은 육류, 소세지, 빵, 초콜릿, 캔디류, 스넥류, 과자류, 피자, 라면, 껌류, 아이스크림류, 스프, 음료수, 차, 기능수, 드링크제, 알콜 및 비타민 복합제 중 어느 하나의 형태일 수 있다.
The health functional food may contain flavoring agents such as various nutrients, vitamins, minerals (electrolytes), synthetic flavors and natural flavors, coloring agents and thickening agents (cheese, chocolate etc.), pectic acid and its salts, alginic acid and its salts, Organic acids, protective colloid thickeners, pH adjusting agents, stabilizers, preservatives, glycerin, alcohols, carbonating agents used in carbonated drinks, and the like. It can also contain natural fruit juices and pulp for the production of fruit juices and vegetable drinks. These components may be used independently or in combination. The health functional food may be in the form of any one of meat, sausage, bread, chocolate, candy, snack, confectionery, pizza, ramen, gum, ice cream, soup, beverage, tea, functional water, .
또한 상기 건강기능식품은 식품첨가물을 추가로 포함할 수 있으며, "식품첨가물"로서의 적합여부는 다른 규정이 없는 한 식품의약품안정청에 승인된 식품첨가물공전의 총칙 및 일반시험법 등에 따라 해당 품목에 관한 규격 및 기준에 의하여 판정한다.
In addition, the health functional food may further include food additives, and the suitability of the food functional food as a "food additive" Standards and standards.
상기 "식품첨가물공전"에 수재된 품목으로 예를 들어, 케톤류, 글리신, 구연산 칼륨, 니코틴산, 계피산 등의 화학적 합성품, 감색소, 감초추출물, 결정셀룰로오스, 고랭색소, 구아검 등의 천연첨가물, L-글루타민산나트륨제제, 면류첨가알칼리제, 보존료제제, 타르색소제제 등의 혼합 제제류 등을 들 수 있다.
Examples of the products that have been used in the above-mentioned "food additives" include natural products such as ketones, chemical products such as glycine, potassium citrate, nicotinic acid and cinnamic acid, sensory coloring matter, licorice extract, crystalline cellulose, high- - Mixed preparations such as a sodium glutamate preparation, a noodle-added alkaline agent, a preservative preparation, a tar coloring agent and the like.
이때, 건강기능식품을 제조하는 과정에서 음료를 포함한 식품에 첨가되는 본 발명에 따른 산천목 추출물은 필요에 따라 그 함량을 적절히 가감할 수 있으며, 바람직하게는 식품 100 중량%에 1 내지 15 중량% 포함되도록 첨가하는 것이 바람직하다.
At this time, the content of the acidophylline extract according to the present invention, which is added to the food containing beverages in the process of manufacturing the health functional food, can be appropriately increased or decreased as needed, and preferably 1 to 15 wt% It is preferable to add them so as to be included.
본 발명은 골질환의 예방 또는 치료에 효과적인 천연 추출물로서, 골질환의 예방 또는 치료 조성물로 약학적으로 이용 가능할 뿐 아니라 건강기능식품으로서도 유용하게 이용될 수 있다.
The present invention is a natural extract effective for prevention or treatment of bone diseases, and can be used not only as a pharmaceutical composition for preventing or treating bone diseases, but also as a health functional food.
도 1은, 본 발명의 일 실시예에 따른 산천목 추출물(WEAT) 처리 농도에 따른 (A) TRAP 염색 및 (B) TRAP 양성의 다핵성 거대 파골세포(Oc)의 수 분석 결과를 나타낸 것이다.
도 2는, 본 발명의 일 실시예에 따른 RANKL에 의해 유도된 BMM으로부터의 파골세포 분화에 대한 산천목 추출물(WEAT) 처리 농도에 따른 (A) TRAP 염색, (B) TRAP 효소 활성 및 (C) TRAP 양성의 다핵성 거대 파골세포(Oc)의 수 분석 결과를 나타낸 것이다.
도 3은, 본 발명의 일 실시예에 따른 파골세포 골흡수능에 대한 산천목 추출물(WEAT) 처리 농도에 따른 (A) TRAP 염색 및 파골세포에 의한 resoption pit 이미지, (B) TRAP 양성의 다핵성 거대 파골세포(Oc) 수 및 (C) 흡수 면적 그래프를 나타낸 것이다.
도 4는, 본 발명의 일 실시예에 따른 산천목 추출물(WEAT) 농도별 세포독성 결과 그래프를 나타낸 것이다.
도 5는, 본 발명의 일 실시예에 따른 산천목 추출물(WEAT) 처리에 대한 c-Fos 및 NFATc1 발현에 대한 western blot 분석 결과를 나타낸 것이다.
도 6은, 본 발명의 일 실시예에 따른 산천목 추출물(WEAT) 처리에 대한 MAPK 및 NF-κB 신호전달계에 대한 western blot 결과를 나타낸 것이다.
도 7은, 본 발명의 일 실시예에 따른 산천목 추출물(WEAT) 처리에 의한 조골전구세포에서의 (A) RANKL mRNA 발현 및 (B) OPG mRNA 발현에 대한 QPCR 분석 결과 그래프를 나타낸 것이다.
도 8은, 본 발명의 일 실시예에 따른 산천목 추출물(WEAT) 처리에 대한 c-Fos 및 NFATc1 발현에 대한 QPCR 분석 결과를 나타낸 것이다.
도 9는, 본 발명의 일 실시예에 따른 실험동물에 대한 약물 투여 일정을 도식화한 것이다.
도 10은, 본 발명의 일 실시예에 따른 산천목 추출물(WEAT) 투여에 따른 (A) micro-CT 결과, (B) bone volume/trabecular volume(BV/TV), (C) Trabecular Thinckness(Tb.Th), (D) Trabecular number(Tb.N) 및 (E) Trabecular separation(Tb.Sp)에 대한 결과를 나타낸 것이다. FIG. 1 shows the results of (A) TRAP staining and (B) TRAP-positive polynuclear giant osteoclast (Oc) analysis according to the treatment concentration of an acidophyllous extract (WEAT) according to an embodiment of the present invention.
FIG. 2 is a graph showing (A) TRAP staining, (B) TRAP enzyme activity, and (C) antioxidative activity depending on the concentration of acid precipitation (WEAT) treatment on osteoclast differentiation from BMM induced by RANKL according to an embodiment of the present invention. ) TRAP positive multinucleated giant osteoclasts (Oc).
FIG. 3 is a graph showing (A) TRAP staining and resorption pit images by osteoclasts, (B) TRAP-positive polynuclear Large osteoclast (Oc) number, and (C) absorption area.
FIG. 4 is a graph showing a cytotoxic result according to the concentration of the acidophyll extract (WEAT) according to an embodiment of the present invention.
FIG. 5 shows the results of western blot analysis for the expression of c-Fos and NFATc1 in the treatment with an acidophyll extract (WEAT) according to an embodiment of the present invention.
Figure 6 shows western blot results for the MAPK and NF-κB signal transduction systems for the treatment of the acidic tree extract (WEAT) according to one embodiment of the present invention.
FIG. 7 is a graph showing the results of QPCR analysis of (A) RANKL mRNA expression and (B) OPG mRNA expression in osteogenic precursor cells by treatment with an aqueous acid extract (WEAT) according to an embodiment of the present invention.
FIG. 8 shows the QPCR analysis results for the expression of c-Fos and NFATc1 in the treatment with an acidophyll extract (WEAT) according to an embodiment of the present invention.
FIG. 9 is a schematic diagram illustrating a drug administration schedule for an experimental animal according to an embodiment of the present invention.
FIG. 10 shows microcontrast results (A), (B) bone volume / trabecular volume (BV / TV), (C) trabecular thinning (Tb .Th), (D) Trabecular number (Tb.N), and (E) Trabecular separation (Tb.Sp).
이하, 하기 제조예 및 실시예에 의하여 본 발명을 더욱 상세하게 설명하고자 한다. 단, 하기 제조예 및 실시예는 본 발명을 예시하기 위한 것일 뿐 본 발명의 범위가 이들만으로 한정되는 것은 아니다.
Hereinafter, the present invention will be described in more detail with reference to the following Production Examples and Examples. However, the following Preparation Examples and Examples are for illustrating the present invention, but the scope of the present invention is not limited thereto.
실시예Example : 산천목 추출물의 제조: Manufacture of Sansung Tree Extract
산천목 50 g을 약탕기에 넣고 증류수 1 ℓ를 가하여 1시간 침적시킨 후 115℃에서 3~4시간 가열추출한 후 여과하여 최종 부피가 100 ㎖가 되게 한 후 동결건조 하였다. 증류수로 다시 녹인 산천목 열수추출물(WEAT)를 실험에 사용하였다.
50 g of mountain stream was placed in a hot water bath, and 1 L of distilled water was added thereto. After 1 hour of immersion, the mixture was heated at 115 ° C. for 3 to 4 hours, filtered and finally lyophilized to a final volume of 100 mL. (WEAT), which was dissolved in distilled water, was used for the experiment.
실험예Experimental Example
1: One:
inin
--
vitrovitro
분석 analysis
1) TRAP 활성 및 다핵성 파골세포 수 분석1) Analysis of TRAP activity and polynuclear osteoclast number
파골세포는 마우스의 골수세포로부터 얻었다. 골수세포는 M-CSF(60 ng/㎖)를 함유한 10% FBS로 이뤄진 α-MEM에서 3일 동안 배양하여 골수 세포 유래 대식세포(BMM)를 수득하였으며, 이를 파골세포 전구 세포로 사용하였다. 파골세포 생성을 위해, BMM를 M-CSF(60 ng/㎖) 및 RANKL(100 ng/㎖)와 4일 동안 배양하였다. 조골전구세포 및 골수세포를 포함하는 공생배양으로부터 파골세포 생성을 위해, 조골전구세포는 신생마우스의 두개골로부터 준비하였다. 골수세포 및 조골전구세포는 1.25(OH)2D3(10 nM)의 존재하에 6일 동안 공생배양하였다. 배양된 세포는 TRAP 활성 측정을 위해 고정 후 기질(p-나이트로페닐포스페이트, p-nitrophenyl phosphate)을 처리한 후 405 nm 흡광도에서 측정하였고, 다핵성 파골세포 수 분석을 위해서 배양된 세포를 TRAP 염색 후 현미경으로 관찰하여 핵이 3개 이상인 TRAP 양성세포 수를 세었다.
Osteoclasts were obtained from mouse bone marrow cells. Bone marrow cells were cultured in α-MEM containing 10% FBS containing M-CSF (60 ng / ml) for 3 days to obtain bone marrow-derived macrophages (BMM), which were used as osteoclast precursor cells. For osteoclast generation, BMM was cultured with M-CSF (60 ng / ml) and RANKL (100 ng / ml) for 4 days. For osteoclastogenesis from syngeneic cultures containing osteoprogenitor cells and bone marrow cells, osteoprogenitor cells were prepared from the skull of neonatal mice. Bone marrow cells and osteoprogenitor cells were co-cultured for 6 days in the presence of 1.25 (OH) 2 D 3 (10 nM). The cultured cells were treated with post-fixation substrate (p-nitrophenyl phosphate) for measurement of TRAP activity, and then measured at 405 nm absorbance. The cells cultured for analysis of polynuclear osteoclasts were subjected to TRAP staining The number of TRAP-positive cells with three or more nuclei was counted by observation with a microscope.
① 조골전구세포와 골수세포의 공생배양으로부터 파골세포 분화에 대한 산천목 추출물(WEAT)의 효과(1) The effect of acidophore extract (WEAT) on the osteoclast differentiation from the synovial culture of osteoprogenitor cells and bone marrow cells
조골전구세포와 골수세포의 공생배양으로 유도된 파골세포 분화에 대한 산천목 추출물의 효과를 확인하기 위하여, 조골전구세포와 골수세포의 공생배양에 1.25(OH)2D3(VitD3; 10 nM) 및 산천목 추출물을 0 ㎍/㎖, 10 ㎍/㎖, 25 ㎍/㎖, 50 ㎍/㎖ 및 100 ㎍/㎖ 농도로 6일 동안 처리한 후 TRAP 염색 및 TRAP 양성의 다핵성 거대 파골세포(Oc)의 수를 확인하였으며, 그 결과를 도 1에 나타내었다. (OH) 2 D 3 (
도 1에 나타난 바와 같이, 산천목 추출물(WEAT) 10 ㎍/㎖, 25 ㎍/㎖, 50 ㎍/㎖ 및 100 ㎍/㎖ 농도로 처리한 결과 1.25(OH)2D3(10 nM)에 의해 유도되는 파골세포 분화를 각각 9%, 66%, 85% 및 100% 억제함을 확인하였다.
As shown in FIG. 1, treatment with 1.25 (OH) 2 D 3 (10 nM) resulted in treatment with 10 ㎍ / ㎖, 25 ㎍ / ㎖, 50 ㎍ / ㎖ and 100 ㎍ / Induced osteoclast differentiation by 9%, 66%, 85% and 100%, respectively.
② RANKL에 의한 bone marrow-derived macrophage(BMM)으로부터 파골세포 분화에 대한 산천목 추출물(WEAT)의 효과(2) Effect of acid extract (WEAT) on osteoclast differentiation from bone marrow-derived macrophage (BMM) by RANKL
RANKL에 의해 유도된 BMM으로부터의 파골세포 분화에 대한 산천목 추출물(WEAT)의 효능을 확인하기 위하여, BMM 세포 배양에 RANKL(100 ng/㎖) 및 산천목 추출물(WEAT, 0 ㎍/㎖, 5 ㎍/㎖, 10 ㎍/㎖, 25 ㎍/㎖, 50 ㎍/㎖ 및 100 ㎍/㎖)을 4일 동안 처리한 후 TRAP 염색, TRAP 효소 활성 및 다핵성 파골세포 수를 확인하였으며, 그 결과를 도 2에 나타내었다. RANKL (100 ng / ㎖) and acid tree extract (WEAT, 0 ㎍ / ㎖, 5 ㎎ / ㎖) were added to the BMM cell culture in order to confirm the efficacy of the acidic tree extract (WEAT) on the osteoclast differentiation from RANKL- TRAP staining, TRAP enzyme activity and polynuclear osteoclast number were confirmed after treatment for 4 days. The results were as follows: 1. 2.
도 2에 나타난 바와 같이, 산천목 추출물(WEAT)를 5 ㎍/㎖, 10 ㎍/㎖, 25 ㎍/㎖, 50 ㎍/㎖ 및 100 ㎍/㎖ 농도로 처리한 결과 RANKL에 의해 유도되는 다핵성 파골세포 분화를 각각 29%, 69%, 94%, 100% 및 100% 억제함을 확인하였다.
As shown in FIG. 2, the treatment with a concentration of 5 ㎍ / ㎖, 10 ㎍ / ㎖, 25 ㎍ / ㎖, 50 ㎍ / ㎖ and 100 ㎍ / And inhibited osteoclast differentiation by 29%, 69%, 94%, 100% and 100%, respectively.
2) 파골세포 골흡수능 분석2) Osteoclast bone resorption assay
콜라겐-겔로 코팅한 배양접시에서 1.25(OH)2D3(10 nM)와 프로스타글란딘 E2(100 nM)의 존재하에 조골세포전구세포와 골수세포를 6일 동안 공생배양하여 파골세포를 생성하였다. 성숙한 다핵성 파골세포를 CaP가 코팅된 플레이트(Osteo Assy Surface, corning, NY, USA)로 옮긴 후 증류수(vehicle) 또는 산천목 추출물(WEAT, 50 ㎍/㎖ 및 100 ㎍/㎖)를 처리하였다. 24시간 후, TRAP 염색과 다핵성 파골세포 수를 확인하였다. 파골세포에의한 resoption pit은 락스를 이용해 파골세포를 제거한 후 현미경 사진촬영 및 image J로 흡수 면적을 분석하였으며, 그 결과를 도 3에 나타내었다.Osteoclast precursor cells and bone marrow cells were co-cultured for 6 days in the presence of 1.25 (OH) 2 D 3 (10 nM) and prostaglandin E2 (100 nM) in a collagen-coated culture dish to produce osteoclasts. Mature polynucleated osteoclasts were transferred to CaP coated plates (Osteo Assy Surface, Corning, NY, USA) and treated with vehicle or acid tree extracts (WEAT, 50 μg / ml and 100 μg / ml). Twenty-four hours later, TRAP staining and polynuclear osteoclast number were confirmed. Resorption pit by osteoclast was obtained by removing the osteoclast using Lax and then microscopically photographing and analyzing the area of absorption by image J, and the result is shown in Fig.
도 3에 나타난 바와 같이, 산천목 추출물(WEAT)를 100 ㎍/㎖로 처리한 결과 파골세포의 수에는 영향이 없이 흡수 면적을 27% 억제하는 것을 확인하였다.
As shown in FIG. 3, treatment with 100 ㎍ / ㎖ of SUNCHOOL extract (WEAT) showed that the absorption area was inhibited by 27% without affecting the number of osteoclasts.
3) 세포독성 시험3) Cytotoxicity test
BMM 세포에서 산천목 추출물(WEAT)의 세포독성을 확인하기 위하여, 과중 추출물(WEAT, 5 ㎍/㎖, 10㎍/㎖, 25㎍/㎖, 50 ㎍/㎖ 및 100㎍/㎖)을 처리하여 관찰하였다. BMM 세포(1.2×104 cell/well)는 M-CSF(60 ng/㎖) 존재 하에 96-well plate에서 2일 동안 시료와 함께 배양하였다. Cell counting Kit-8(CCK-8)은 세포독성 측정에 사용하였으며, 데이터는 3번 반복실험의 평균과 표준오차로 나타내었다. 그 결과를 도 4에 나타내었다. (WEAT, 5 ㎍ / ㎖, 10 ㎍ / ㎖, 25 ㎍ / ㎖, 50 ㎍ / ㎖ and 100 ㎍ / ㎖) were treated in order to confirm the cytotoxicity of the acidic tree extract (WEAT) Respectively. BMM cells (1.2 × 10 4 cells / well) were incubated with the samples for 2 days in a 96-well plate in the presence of M-CSF (60 ng / ml). Cell counting Kit-8 (CCK-8) was used to measure cytotoxicity, and data were expressed as mean and standard error of three replicate experiments. The results are shown in Fig.
도 4에 나타난 바와 같이, 산천목 추출물(WEAT) 5 ㎍/㎖, 10㎍/㎖, 25 ㎍/㎖ 및 50 ㎍/㎖ 농도로 처리한 BMM에서는 세포독성이 나타나지 않았으며, 25 ㎍/㎖, 50 ㎍/㎖ 및 100 ㎍/㎖ 농도 처리에서 생장을 촉진시키는 것을 확인하였다.
As shown in FIG. 4, no cytotoxicity was observed in BMM treated with 5 ㎍ / ㎖, 10 ㎍ / ㎖, 25 ㎍ / ㎖ and 50 ㎍ / 50 [mu] g / ml and 100 [mu] g / ml, respectively.
3) Western blot 분석3) Western blot analysis
BMM는 인산완충식염수(PBS)로 세척하고 50 mM tris-염산(pH 8.0), 5 nM EDTA, 150 mM 염화나트륨, 1% NP-40, 0.1% SDS, 1 nM PMSF, 분해효소 저해제 혼합 타블렛 및 인산화효소 저해제 혼합 타블렛으로 구성된 단백질 추출 완충용액(protein extraction buffer)에 녹였다. 세포 분해물은 4℃에서 10,000 ×g으로 15분 동안 원심분리하였다. 단백질 농도는 BCA 단백질 분석 키트를 사용하여 측정하였으며, 단백질 시료(30 ㎍)은 시료 완충액(100 nM tris-염산, 2% SDS, 1% 2-메캅토에탄올, 2% 글리세롤 및 0.01% 브로모페놀 블루, pH 7.6)과 혼합하고 5분 동안 95℃에서 배양하고 10% 폴리아크릴아민 겔에 점적하였다. 전기영동법은 mini protean 3 cell(Bio-Rad, Hercules, CA, USA)를 사용하여 수행하였으며, 겔 위에 분리된 단백질은 PVDF 막으로 옮겼다. 막은 blocking 완충액(10 mM tris-염산(pH 7.5), 150 mM 염화나트륨, 0.1% Tween 20 및 3% non-fat dry milk) 내에서 배양한 후, 1:1000으로 희석된 1차 항체와 함께 4℃에서 overnight 동안 배양하였다. 세척 완충액(10 mM tris-염산(pH 7.5), 150 mM 염화나트륨 및 0.1% Tween 20)으로 각 10분 동안 3차례 세척한 후, 1:2000으로 희석된 2차 항체(cell Signaling Technology Inc., Danvers, MA, USA)와 1시간 동안 배양하였다. 그 후, 막을 세척 완충액(10 mM tris-염산(pH 7.5), 150 mM 염화나트륨 및 0.1% Tween 20)으로 10분 동안 3차례 세척한 후 SuperSignal West Femto Maximum Sensitivity Substrate를 사용하였다. 화학발광 신호는 LAS-3000 Luminescent image analyzer로 검출하였다.
BMM was washed with phosphate buffered saline (PBS) and resuspended in 50 mM tris-hydrochloric acid (pH 8.0), 5 nM EDTA, 150 mM sodium chloride, 1% NP-40, 0.1% SDS, 1 nM PMSF, Was dissolved in protein extraction buffer consisting of enzyme-inhibitor mixed tablet. Cell lysates were centrifuged at 4O < 0 > C at 10,000 xg for 15 minutes. Protein concentration was measured using a BCA protein assay kit. Protein samples (30 μg) were resuspended in sample buffer (100 nM tris-hydrochloric acid, 2% SDS, 1% 2-mercaptoethanol, 2% glycerol and 0.01% Blue, pH 7.6) and incubated for 5 minutes at 95 ° C and loaded onto 10% polyacrylamine gel. Electrophoresis was performed using mini protean 3 cells (Bio-Rad, Hercules, Calif., USA), and proteins separated on the gel were transferred to a PVDF membrane. The membranes were incubated in blocking buffer (10 mM tris-HCl (pH 7.5), 150 mM sodium chloride, 0.1
① 산천목 추출물(WEAT)의 c-Fos 및 NFATc1 발현에 미치는 영향① Effect on the expression of c-Fos and NFATc1 in the extracts of sunflower (WEAT)
파골세포 분화의 중추적인 전사인자인 c-Fos 및 NFATc1 발현에 대한 산천목 추출물(WEAT)의 억제 효과를 확인하기 위하여, BMM 세포 배양에 증류수(vehicle) 또는 산천목 추출물(WEAT, 50 ㎍/㎖)을 3시간 동안 전처리한 후 RANKL(100 ng/㎖)를 처리하여 0, 1, 2, 3, 4일에 단백질을 수득하여, Wetern blot 분석을 수행하였다. p38은 western blot의 loading control로 사용하였으며, 그 결과를 도 5에 나타내었다.(WEAT, 50 ㎍ / ㎖) was added to the BMM cell culture in order to examine the inhibitory effect of the extracts of catechin (WEAT) on the expression of c-Fos and NFATc1, the key transcription factors of osteoclast differentiation ) Was pretreated for 3 hours and treated with RANKL (100 ng / ml) to obtain proteins on
도 5에 나타난 바와 같이, BMM에서 RANKL 처리에 의한 c-Fos 및 NFATc1의 단백질 발현 증가가 산천목 추출물(WEAT) 처리에 의해 감소되는 것을 확인하였다.
As shown in FIG. 5, it was confirmed that the increase in the protein expression of c-Fos and NFATc1 by RANKL treatment in BMM was reduced by treatment with the acidophilic extract (WEAT).
② 산천목 추출물(WEAT)의 MAPK 및 NF-κB 신호전달계에 미치는 영향② Effect of acid tree extract (WEAT) on MAPK and NF-κB signal transduction system
RANKL에 의해 활성화 되는 파골세포 분화와 관련된 MAPK 및 NF-κB 신호전달계에 대한 산천목 추출물(WEAT)의 영향을 확인하기 위하여, BMM 세포 배양에 증류수(vehicle) 또는 산천목 추출물(WEAT, 50 ㎍/㎖)을 3시간 동안 전처리한 후 RANKL(100 ng/㎖)를 0, 5, 15 및 30분 동안 처리하였으며, MAPKs(ERK, JNK, p38) 및 NF-κB 신호전달계 단백질(p65, IκB)의 인산화 정도를 Western blot으로 확인하였으며 그 결과를 도 6에 나타내었다. (WEAT, 50 ㎍ / ㎖) was added to the BMM cell culture in order to examine the effect of the acidophore (WEAT) on MAPK and NF-κB signaling system associated with RANKL-induced osteoclast differentiation, (ERK, JNK, p38) and NF-κB signaling pathway proteins (p65, IκB) were treated with RANKL (100 ng / ml) for 0, 5, 15 and 30 minutes The degree of phosphorylation was confirmed by Western blot and the results are shown in FIG.
도 6에 나타난 바와 같이, RANKL 처리에 의하여 ERK, JNK, p38, p65 및 IκB의 인산화가 증가하였고, 산천목 추출물(WEAT)의 처리에 의하여 RANKL 유도에 의한 JNK 및 p65의 인산화가 억제되는 것을 확인하였다.
As shown in FIG. 6, phosphorylation of ERK, JNK, p38, p65 and IκB was increased by RANKL treatment, and phosphorylation of JNK and p65 by RANKL induction was inhibited by treatment with acidophilic extract (WEAT) Respectively.
4) real-time quantitative PCR(QPCR) 분석4) Real-time quantitative PCR (QPCR) analysis
조골세포 및 BMM 세포로 부터의 total RNA는 RNA-spin total RNA Extraction Kit(인트론)로 분리하였다. first-strand cDNA 1 ㎍ total RNA, 1 μM oligo-dT18 프라이머, AccuPower RT-PreMix(바이오니아)을 이용하여 합성하였다. 그 후, SYBR green-based QPCR 증폭은 first-strand cDNA 및 10 pmol 프라이머를 사용하여 AccuPower GreenStar qPCR Master Mix(바이오니아) 및 Applied Biosystems 7500 Real-time PCR system을 이용하여 수행하였다. 모든 반응은 3번 반복하였으며, 데이터는 2-△△ CT 방법으로 분석하였다. HPRT는 내부표준으로 사용하였다.
Total RNA from osteoblasts and BMM cells was separated by RNA-spin total RNA Extraction Kit (intron). first-
① 조골전구세포에서의 RANKL 및 OPG 발현에 대한 산천목 추출물(WEAT)의 효과(1) Effect of acidophyll extract (WEAT) on the expression of RANKL and OPG in osteogenic precursor cells
조골전구세포에서의 RANKL 및 OPG 발현에 대한 산천목 추출물(WEAT)의 효과를 확인하기 위하여, 조골전구세포에 산천목 추출물(WEAT)를 50 ㎍/㎖ 농도로 3시간 동안 전처리 후 VitD3(1.25(OH)2D3(10 nM))를 처리하고 24시간 후 real-time PCR로 RANKL 및 OPG mRNA 발현을 확인하였으며, 그 결과를 도 7에 나타내었다. (WEAT) was pretreated with a concentration of 50 ㎍ / ㎖ for 3 hours, and VitD 3 (1.25 ㎍ / ㎖) was added to the osteogenic precursor cells. (OH) 2 D 3 (10 nM)). After 24 hours, the expression of RANKL and OPG mRNA was confirmed by real-time PCR. The results are shown in FIG.
도 7에 나타난 바와 같이, 산천목 추출물(WEAT)는 조골전구세포에서의 RANKL 발현 감소 효과를 나타내었으나, VitD3(1.25(OH)2D3(10 nM))에 의한 RANKL 발현 증가에는 영향을 미치지 않았다. 또한, 산천목 추출물(WEAT)는 VitD3(1.25(OH)2D3(10 nM))에 의한 OPG 발현 감소를 억제하는 것을 확인하였다.
As shown in FIG. 7, the extracts of acidophilus extract (WEAT) showed a decrease in RANKL expression in osteolytic progenitor cells, but the increase in RANKL expression by VitD 3 (1.25 (OH) 2 D 3 I was not crazy. In addition, it was confirmed that the extract of sunflower (WEAT) inhibited the decrease of OPG expression by VitD 3 (1.25 (OH) 2 D 3 (10 nM)).
② 산천목 추출물(WEAT)의 c-Fos 및 NFATc1 발현에 미치는 영향② Effect of acid extract (WEAT) on c-Fos and NFATc1 expression
파골세포 분화의 중추적인 전사인자인 c-Fos 및 NFATc1 발현에 대한 산천목 추출물(WEAT)의 억제 효과를 확인하기 위하여, BMM 세포 배양에 증류수(vehicle) 또는 산천목 추출물(WEAT, 50 ㎍/㎖)을 3시간 동안 전처리한 후 RANKL(100 ng/㎖)를 처리하여 0, 1, 2, 3, 4일에 RAN 및 단백질을 수득하여, real-time PCR 분석을 수행하였다. 그 결과를 도 8에 나타내었다.(WEAT, 50 ㎍ / ㎖) was added to the BMM cell culture in order to examine the inhibitory effect of the extracts of catechin (WEAT) on the expression of c-Fos and NFATc1, the key transcription factors of osteoclast differentiation ) Was pretreated for 3 hours and RANKL (100 ng / ml) was treated to obtain RAN and proteins at 0, 1, 2, 3 and 4 days, and real-time PCR analysis was performed. The results are shown in Fig.
도 8에 나타난 바와 같이, BMM에서 RANKL 처리에 의한 c-Fos 및 NFATc1의 mRNA 및 단백질 발현 증가가 산천목 추출물(WEAT) 처리에 의해 감소되는 것을 확인하였다.
As shown in FIG. 8, it was confirmed that the increase of mRNA and protein expression of c-Fos and NFATc1 by RANKL treatment in BMM was reduced by the treatment with acidophilic extract (WEAT).
실험예Experimental Example
2: 2:
inin
--
vivovivo
분석 analysis
1) 실험동물 및 시료투여1) Experimental animal and sample administration
ICR 6주된 수컷 마우스를 각 7마리씩 4군으로 나누고 5일 동안 1일 2회씩 산천목 추출물을 경구투여 하였으며, 실험 일정을 도 9에 나타내었다.
도 9에 나타난 바와 같이, 증류수 0.2 ㎖ 또는 0.2 ㎖ 증류수에 녹인 산천목 추출물(WEAT, 0.25 g/kg of body weight 또는 0.75 g/kg of body weight)을 1일 2회씩 5일 동안 경구 투여하였다. RANKL(1 mg/kg of body weight) 또는 PBS 50 ㎕를1일 1회, 2일 동안 복강 투여하였다. 투여 5일 째, 마우스에서 대퇴골을 적출하고 10% neutral buffered formalin으로 고정하였다. 하기 표 1에 자세한 실험 군을 나타내었다. As shown in FIG. 9, 0.2 ml of water (0.25 g / kg of body weight or 0.75 g / kg of body weight) dissolved in 0.2 ml of distilled water or 0.2 ml of distilled water was orally administered twice daily for 5 days. RANKL (1 mg / kg body weight) or
2) Micro-computed tomography(Micro-CT) 분석2) Micro-computed tomography (Micro-CT) analysis
RANKL에 의한 대퇴골에서의 골손실 및 산천목 추출물(WEAT)에 의한 억제 효능을 확인하기 위하여 SMX-90CT system(90 kVp, 109 mA, 180-ms integration time; Shimadzu, Kyoto, Japan)으로 micro-CT로 해면골(trabecular bone)을 확인하였다. 또한, bone volume/tissue volume(BV/TV, %), trabecular thichness(Tb.Th, ㎛), trabecular number(Tb.N, 1/mm) 및 trabecular separation(Tb.Sp, ㎛)를 계산하고 TRI/3D-VIE(RATOC System Engineering, Kyoto, Japan)으로 나타내었으며, 그 결과를 도 10에 나타내었다. In order to confirm the inhibitory effect of RANKL on osteolysis in the femur and the inhibition by WEAT, the SMX-90CT system (90 kVp, 109 mA, 180-ms integration time; Shimadzu, Kyoto, Japan) And the trabecular bone was confirmed. We also calculated the bone volume / tissue volume (BV / TV,%), trabecular thichness (Tb.Th, ㎛), trabecular number (Tb.N, 1 / mm) and trabecular separation / 3D-VIE (RATOC System Engineering, Kyoto, Japan). The results are shown in Fig.
도 10에 나타난 바와 같이, RANKL을 투여하지 않은 대조군과 비교하여 RANKL 투여에 의해 BV/TV 68% 감소, Tb.Th 24% 감소, Tb.N 57% 감소 및 Tb.Sp 224% 증가억제 효과를 나타내었다. 또한, 산천목 추출물(WEAT) 0.25 g/kg 경구 투여에 의하여 RANKL 투여에 의한 Tb.Sp 증가만 유의적으로 억제하였으며, 산천목 추출물(WEAT) 0.75 g/kg 경구 투여에 의해서는 RANKL 투여에 의한 BV/TV 감소, Tb.Th 감소, Tb.N 감소 및 Tb.Sp 증가를 모두 억제하였음을 확인하였다. As shown in FIG. 10, RANKL inhibited BV / TV by 68%, Tb.Th by 24%, Tb.N by 57% and Tb.Sp by 224% compared to the control without RANKL Respectively. In addition, only Tb.Sp increase by RANKL administration was significantly inhibited by 0.25 g / kg oral administration of WEACH (acid), and by RANKL administration by 0.75 g / kg oral administration of WEAT BV / TV decrease, Tb.Th decrease, Tb.N decrease, and Tb.Sp increase.
Claims (8)
A pharmaceutical composition for preventing or treating osteoporosis or osteogenesis imperfecta containing an extract of Sanskrit tree as an active ingredient.
According to claim 1, wherein said mountains and rivers neck extract is a pharmaceutical composition, characterized in that is made by extracting the mountains and rivers neck with water, C 1 -4 alcohol or a mixed solvent thereof.
The pharmaceutical composition according to claim 2, wherein the extraction is hot water extraction, ultrasonic extraction, room temperature extraction, cold extraction, reflux cooling extraction, or steam extraction.
The pharmaceutical composition according to claim 1, wherein the prevention or treatment of the composition is carried out by inhibiting bone loss by administering the composition.
A health functional food composition for preventing or ameliorating osteoporosis or osteogenesis imperfections containing an extract of Sanskrit tree as an active ingredient.
The method of claim 5, wherein the mountains and rivers neck extract neck mountains and rivers water, C 1 -4 alcohol or a functional food composition, characterized in that is made by extraction with a mixed solvent thereof.
The health functional food composition according to claim 6, wherein the extraction is hot water extraction, ultrasonic extraction, room temperature extraction, cold extraction, reflux cooling extraction or steam extraction.
The pharmaceutical composition according to claim 1, wherein the composition is for the prevention or treatment of osteoporosis.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020120082803A KR101402922B1 (en) | 2012-07-27 | 2012-07-27 | Pharmaceutical composition and functional food for prevention or treatment of bone disease comprising the acer tegmentosum maxim extract |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020120082803A KR101402922B1 (en) | 2012-07-27 | 2012-07-27 | Pharmaceutical composition and functional food for prevention or treatment of bone disease comprising the acer tegmentosum maxim extract |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR20140015084A KR20140015084A (en) | 2014-02-06 |
| KR101402922B1 true KR101402922B1 (en) | 2014-06-03 |
Family
ID=50264872
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020120082803A KR101402922B1 (en) | 2012-07-27 | 2012-07-27 | Pharmaceutical composition and functional food for prevention or treatment of bone disease comprising the acer tegmentosum maxim extract |
Country Status (1)
| Country | Link |
|---|---|
| KR (1) | KR101402922B1 (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102526718B1 (en) * | 2019-04-15 | 2023-05-02 | 한국한의학연구원 | Composition for the preventing and improving menopausal disorder, comprising extract of acer tegmentosum maxim and extract of Rumecis Radix |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20070028829A (en) * | 2005-09-08 | 2007-03-13 | 주식회사 다원 | Composition comprising the extract of dioscorea quinqueloba and acer tegmentosum showing anti-oxidative, anti-aging, anti-lipidperoxidative, anti-edema and expectorant activity |
| KR100927101B1 (en) | 2007-11-05 | 2009-11-13 | 상지대학교산학협력단 | Composition comprising Acer tegmentosum Maxim. extract or salidroside isolated from the same for preventing or treating gastritis and peptic ulcer |
| KR20100080972A (en) * | 2009-01-05 | 2010-07-14 | 김선일 | Fermentation sap of tree sap and using means |
| KR101039053B1 (en) | 2008-10-06 | 2011-06-07 | 대한민국(농촌진흥청장) | Compositions for Treatment and Prevention of Bone Diseases Comprising Extract of Hypericum ascyron |
-
2012
- 2012-07-27 KR KR1020120082803A patent/KR101402922B1/en active IP Right Grant
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20070028829A (en) * | 2005-09-08 | 2007-03-13 | 주식회사 다원 | Composition comprising the extract of dioscorea quinqueloba and acer tegmentosum showing anti-oxidative, anti-aging, anti-lipidperoxidative, anti-edema and expectorant activity |
| KR100927101B1 (en) | 2007-11-05 | 2009-11-13 | 상지대학교산학협력단 | Composition comprising Acer tegmentosum Maxim. extract or salidroside isolated from the same for preventing or treating gastritis and peptic ulcer |
| KR101039053B1 (en) | 2008-10-06 | 2011-06-07 | 대한민국(농촌진흥청장) | Compositions for Treatment and Prevention of Bone Diseases Comprising Extract of Hypericum ascyron |
| KR20100080972A (en) * | 2009-01-05 | 2010-07-14 | 김선일 | Fermentation sap of tree sap and using means |
Also Published As
| Publication number | Publication date |
|---|---|
| KR20140015084A (en) | 2014-02-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR100684194B1 (en) | . A pharmaceutical composition comprising extract of roasted Licorice for treating and preventing bone disease. | |
| KR20120033633A (en) | Composition comprising the curcumin for bone growth-promoting effects | |
| JP2006083151A (en) | Composition for preventing and ameliorating osteoporosis | |
| KR20200079203A (en) | Composition for preventing or treating bon disease comprising extract of blueberry | |
| KR102113099B1 (en) | A composition for prevention or treatment of bone diseases comprising lycopi herba extract | |
| KR101402926B1 (en) | Pharmaceutical composition and functional food for prevention or treatment of bone disease comprising the lactic acid bacteria ferment of hwangryunhaedoktang | |
| KR20110131821A (en) | Composition comprising sauchinone as an active ingredient for preventing or treating insulin resistance | |
| KR101457117B1 (en) | Pharmaceutical composition and functional food for prevention or treatment of bone disease comprising the dryopteris crassithizoma extract | |
| KR101402922B1 (en) | Pharmaceutical composition and functional food for prevention or treatment of bone disease comprising the acer tegmentosum maxim extract | |
| KR101242635B1 (en) | Composition for Prevention or Treatment of Osteoporosis Comprising Extract of Selaginellae Herba | |
| KR101637517B1 (en) | Compositions for preventing or curing obesity comprising vitamin U | |
| KR101735061B1 (en) | Composition containing Artemisia annua extract, artemisinin or dihydroartemisinin for preventing or treating obesity | |
| KR101642409B1 (en) | Pharmaceutical composition and fuctional food composition for prevention or treatment of bone disease comprising the tsaoka fructus extract | |
| CN108452033A (en) | The prevention of bone disease containing mixing Chinese medicinal material extract and therapeutic composition | |
| KR101502465B1 (en) | A pharmaceutical composition comprising Alpinia Officinarum extracts for prevention and treatment of bone diseases or anti-vascular calcification activity | |
| KR20180131770A (en) | A composition comprising extract of Coptis chinensis F. for treating and preventing muscle-related disorder | |
| KR101249930B1 (en) | Compositions comprising extracts of Sorbus commixta and Geranium nepalense for inhibiting osteoclastogenesis and stimulating chondrogenesis | |
| KR101120499B1 (en) | Composition For Preventing And Treating Bone Diseases | |
| KR20120044450A (en) | Composition for prevention or treatment of osteoporosis comprising extract of cirsii herba | |
| KR20210000685A (en) | Composition for preventing or treating bone disease comprising a extract mixture of ulmus bark and cornus officinalis | |
| KR102448274B1 (en) | Composition for preventing, ameliorating or treating bone disease comprising crude polysaccharide fraction of Psoralea corylifolia extract as effective component | |
| KR102532265B1 (en) | Composition for preventing or treating of osteolytic diseases comprising 3-Hydroxyolean-12-en-27-oic acid or derivatives thereof derived from Aceriphyllum rossii | |
| KR102312737B1 (en) | A composition for bone health comprising winter melon seed extract | |
| KR102410703B1 (en) | Composition for preventing, improving or treating bone disease comprising Pyrrosia lingua extract as effective component | |
| KR20130059741A (en) | Pharmaceutical compositions for preventing or treating arthritis comprising euphorbia ebracteolata extracts |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A201 | Request for examination | ||
| E902 | Notification of reason for refusal | ||
| E701 | Decision to grant or registration of patent right | ||
| GRNT | Written decision to grant | ||
| FPAY | Annual fee payment |
Payment date: 20170412 Year of fee payment: 4 |
|
| FPAY | Annual fee payment |
Payment date: 20180410 Year of fee payment: 5 |